Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

touchIMMUNOLOGY

Education, Conference Coverage and Articles

Speciality Filter
Or View our Specialities Page

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an ...

Mark CompleteCompleted
BookmarkBookmarked

International experts from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) have recently partnered to produce the much-anticipated classification criteria for antiphospholipid syndrome (APS), which were published in Arthritis & Rheumatology in August 2023.1 ...

Mark CompleteCompleted
BookmarkBookmarked

Chronic back pain (CBP), defined as back pain lasting for 3 months or more, is the most common pain condition globally.1 Greater healthcare utilization, productivity limitations and poor quality of life have immediate and long-term impacts on patients and the healthcare ...

Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of touchREVIEWS in RMD! We’re excited to share a dynamic collection of articles that highlight the evolving landscape of rheumatic and musculoskeletal diseases (RMDs). We open the issue by delving into a series of ...

35 mins
Sponsored Content
touchEXPERT BRIEFING
For HCPs in: Global, excluding UK

Watch leading experts discuss updates in the treatment of systemic lupus erythematosus (SLE), lupus nephritis (LN) and Sjögren’s disease, based on data presented at EULAR 2024.

18 mins
Sponsored Content
touchEXPERT BRIEFING
For HCPs in: Global, excluding US and France

Watch Drs Ronald Vender, Richard Warren and Xenofon Baraliakos discuss UCB’s contributions to the treatment of immunological disease.

Want to be featured in touchReviews in RMD?

Share your knowledge, influence clinical practices and enhance patient care in Immunology today!

  • Peer-reviewed, free-to-access
  • Accepting reviews, research and editorials
  • No article processing fees
  • Digital features and plain language summaries
  • Multichannel content distribution for maximum visibility
Mark CompleteCompleted
BookmarkBookmarked
Gatr-Alnada Gheriani, Rebecca Tuetken, Petar S Lenert

This corrects the article: “Gheriani GA, Tuetken R and Lenert P. Lane–Hamilton Syndrome: A Vasculitis Mimic Presenting with Diffuse Alveolar Haemorrhage and Positive ANCA Testing. touchREVIEWS in RMD. 2024;3(1):37–42” The patient consent statement was added incorrectly due to an editorial ...

Mark CompleteCompleted
BookmarkBookmarked

It is increasingly recognized that autoimmune rheumatic diseases (ARDs) can affect people of any age, starting from early childhood and continuing until later in life. Furthermore, in recent decades, it has become apparent that Sjögren disease (SjD), commonly diagnosed ...

Mark CompleteCompleted
BookmarkBookmarked

This editorial outlines a clinical approach to patients with periodic inflammation of unknown origin despite initial rational and targeted investigation. The focus of the editorial is on the recognition and diagnosis of systemic autoinflammatory diseases (SAIDs). Although rare, SAIDs are ...

Mark CompleteCompleted
BookmarkBookmarked

The global burden of disease is heavily impacted by the increased prevalence of chronic inflammatory rheumatic diseases (CIRDs [rheumatoid arthritis (RA), spondyloarthritis (SpA), connective tissue diseases (CTDs) crystal arthropathies and polyarticular osteoarthritis (OA)]), which are prevalent chronic non-communicable diseases associated ...

Mark CompleteCompleted
BookmarkBookmarked

Systemic lupus erythematosus (SLE) predominantly affects females and is characterized by multisystem involvement.1,2 Despite advancements in therapeutics, patients with SLE still experience poor health-related quality of life (HRQoL).3 Systemic sclerosis (SSc) is characterized by vasculopathy and fibrosis of the skin ...

Mark CompleteCompleted
BookmarkBookmarked

Diffuse alveolar haemorrhage (DAH) is associated with high morbidity and mortality. The causes of DAH are diverse, and include rheumatologic conditions such as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), Systemic lupus erythematosus (SLE) and Goodpasture’s syndrome (Table 1). Rheumatologists ...

Mark CompleteCompleted
BookmarkBookmarked

Although biological disease-modifying antirheumatic drugs (bDMARDs) are significantly cheaper now that biosimilar agents are available, they still represent a significant cost to health services worldwide, particularly since their prescription has only increased since the thresholds for commencing this treatment have ...

Mark CompleteCompleted
BookmarkBookmarked
Michael Alsharkawy, Alice Mason, May Lwin

Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disorder affecting skin, joints, kidneys, the heart, lungs, the brain and blood cells, and is characterized by heterogeneous presentations and severity. It is more common in females than males, with a ratio ...

Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest issue of touchREVIEWS in RMD, which aims to provide healthcare professionals with a wide range of topical articles in the field of rheumatic and musculoskeletal diseases (RMDs). We begin with an informative practice pearl from Sun ...

Mark CompleteCompleted
BookmarkBookmarked

Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints but may be accompanied by systemic and extra-articular manifestations.1,2 Patients with RA are associated with a higher mortality rate compared with the general population and with increased ...

Mark CompleteCompleted
BookmarkBookmarked

Biologics are medications derived from biological sources used to treat several immune-mediated inflammatory diseases. These medications interfere with autoimmune processes by inhibiting specific molecular or cellular targets. They are highly effective medications, mostly used in cases of moderate-to-severe disease activity. ...

Mark CompleteCompleted
BookmarkBookmarked

Standardization of the assessment of disease activity in patients with rheumatoid arthritis (RA) has made a big difference in the comparability of clinical trials and in treatment processes in clinical practice.1–3 Disease activity is the underlying driver for radiographic progression, ...

8 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Canada, China, Colombia, Costa Rica, Denmark, Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Guatemala, Hong Kong, Hungary, Iceland, Italy, Kuwait, Lebanon, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Singapore, South Korea, Spain, Sudan, Sweden, Taiwan, Thailand, The Netherlands, and UAE

Watch highlights of three ADVENT symposia presented at EADV 2023

Load More...

Editorial Board

Introducing the Editorial Board of touchREVIEWS in Immunology, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.

View All Members

Peter Taylor

Editor-in-Chief

Rheumatoid Arthritis

Close Popup

Peter Taylor

Editor-in-Chief

Head of Clinical Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

Oxford, UK

Biography

Peter C Taylor holds the Norman Collison chair of musculoskeletal sciences at the University of Oxford and is a Fellow of St. Peter’s College. He is Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge and his first degree was in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for research on pathogenesis of arthritis. Professor Taylor has specialist clinical interests in inflammatory arthritis. He has over 25 years’ experience in clinical trial design in studies of biologic and small molecular therapies in rheumatoid arthritis and ankylosing spondylitis. In experimental medicine studies, Professor Taylor employs targeted therapies as probes of pathogenesis to investigate the in vivo biology of the target in the pathobiology of the disease phenotype under investigation.

Jérôme Avouac

Editorial Board member

Jérôme Avouac

Editorial Board member

Rheumatoid Arthritis

Close Popup

Jérôme Avouac

Editorial Board member

Senior Rheumatologist at Cochin Hospital and Professor at the University of Paris, Rheumatology Department, Paris, France

Paris, France

Biography

Jérôme Avouac is a senior rheumatologist at Cochin Hospital and Professor at the University of Paris. He is responsible for a sector of day hospitalisation in the Rheumatology department, whose recruitment is mainly composed of patients with chronic inflammatory rheumatic disorders. He established a standardized systematic follow-up of joint involvement and systemic complications of rheumatoid arthritis and other inflammatory rheumatic diseases. Based on this standardized follow-up and clinical studies, he is developing medical approaches of personalized medicine for rheumatoid arthritis. Within the “Pathogenesis And Innovative Therapies In Chronic Fibro-Inflammatory Diseases” team at the Cochin Institute (INSERM U1016 UMR8104), Prof. Avouac leads innovative projects regarding the vascular aspects of inflammatory rheumatic disorders, especially rheumatoid arthritis. He also participates in the preclinical evaluation of anti-fibrotic treatments thanks to a platform of complementary animal models with dermal, pulmonary and vascular fibrosis.

Peter Taylor

Editor-in-Chief

Richard Furie

Editorial Board member

Richard Furie

Editorial Board member

Systemic Lupus Erythematosus

Close Popup

Richard Furie

Editorial Board member

Rheumatologist, Division of Rheumatology, Northwell Health, and Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

Hempstead, NY, USA

Biography

Dr Richard Furie is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the Hospital’s systemic lupus erythematosus (SLE) and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, he has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. He has served on many committees of the American College of Rheumatology and was named a Master of the College in 2018.

Jérôme Avouac

Editorial Board member

Gil Melmed

Faculty member

Gil Melmed

Faculty member

Gastroenterology

Close Popup

Gil Melmed

Faculty member

Co-Director, Inflammatory Bowel and Immunobiology Research Institute, and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, US

Los Angeles, CA, USA

Biography

Gil Y Melmed, MD, MS, is the Co-Director of the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in Los Angeles, CA, USA. He earned his medical degree from Albert Einstein College of Medicine in the Bronx, New York, and master of science in clinical research from the University of California, School of Medicine (UCLA), Los Angeles. He completed his gastroenterology fellowship at UCLA also.

Dr Melmed has authored or co-authored more than 150 articles in peer-reviewed journals and several book chapters. Dr Melmed has served as Associate Editor of the American Journal of Gastroenterology, and clinical research editor for Inflammatory Bowel Disease. His interests include clinical outcomes and quality of care in inflammatory bowel disease (IBD), as well as translational prognostic and therapeutic strategies to improve inflammation and clinical outcomes. He has led or participated in the development of quality indicators for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, the National Quality Forum, and the Canadian Crohn’s and Colitis organizations.

Richard Furie

Editorial Board member

Peter Taylor

Editor-in-Chief
Advertisement
  • touchIMMUNOLOGY touchIMMUNOLOGY

    Register Now!

    Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

    • Save your progress for video
    • Keep track of your CME credits
    • Add personalised learning notes
    • Receive updates from course leaders and faculty
    • Be the first to hear about new and exciting interactive learning opportunities
    Close Popup